Anticuerpo ensayado en hogar de ancianos redujo en 80% el riesgo de Covid-19 colombia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from colombia.com Daily Mail and Mail on Sunday newspapers.
Published January 22, 2021 5:08am WASHINGTON - A synthetic antibody developed by Eli Lilly reduced the risk of contracting Covid-19 by 80 percent in a study of nursing home residents when used preventatively, the company said Thursday. Though the result is only preliminary and awaiting peer review, the finding was hailed as highly promising by experts, who said it meant that the infused therapy had the potential to complement vaccines. We are exceptionally pleased with these positive results, which showed bamlanivimab was able to help prevent COVID-19, substantially reducing symptomatic disease among nursing home residents, some of the most vulnerable members of our society, said Daniel Skovronsky, the company s chief scientific officer, using the trade name for the antibody.
Azithromycin is an antibiotic which is known to treat inflammation in patients
It had been speculated it may help people suffering with severe Covid-19
Hospitalised patients suffer inflammation as their immune system attacks itself
But RECOVERY trial has now found it has no impact on chance of death, hospital stay or likelihood of needing to be put on a ventilator